Phase II study of lonidamine in inoperable non-small-cell lung cancer.
31 patients with inoperable non-small-cell lung cancer were treated with Lonidamine at daily doses of 450-900 mg orally. Side effects mostly consisted of myalgias, often severe, and gastrointestinal symptoms. Lonidamine was discontinued in 8 patients because of tumor progression and in 2 on account of side effects. 3 partial responses were observed, 2 in patients with epidermoid tumors.
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000187:drug effects; D011720:Pyrazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D007191:Indazoles; D011720:Pyrazoles; C016371:lonidamine